Differences in Biomarkers in Patients With Heart Failure With a Reduced vs a Preserved Left Ventricular Ejection Fraction

Canadian Journal of Cardiology

Volumn 28, Issue 1, 2012, Pages 62-68

  De Denus, Simon ^a   Lavoie, Joël ^a   Ducharme, Anique ^a   O'Meara, Eileen ^a   Racine, Normand ^a   Sirois, Martin G ^a   Neagoe, Paul Eduard ^a   Zhu, Li ^a   Rouleau, Jean Lucien ^a   White, Michel ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; GELATINASE A; GELATINASE B; NEUROHORMONE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ECHOCARDIOGRAPHY; EXTRACELLULAR MATRIX; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HISTOPATHOLOGY; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SYMPTOM;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY; FEMALE; GATED BLOOD-POOL IMAGING; HEART FAILURE; HUMANS; IMMUNOASSAY; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NEPHELOMETRY AND TURBIDIMETRY; PEPTIDE FRAGMENTS; PROCOLLAGEN; PROGNOSIS; PROTEIN PRECURSORS; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VENTRICULAR FUNCTION, LEFT;

EID: 84856028941     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2011.09.007     Document Type: Article

References (38)

1. Hogg K., Swedberg K., McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004, 43:317-327.
2. Bhatia R.S., Tu J.V., Lee D.S., et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006, 355:260-269.
3. Owan T.E., Hodge D.O., Herges R.M., et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006, 355:251-259.
4. De Keulenaer G.W., Brutsaert D.L. Systolic and diastolic heart failure: different phenotypes of the same disease?. Eur J Heart Fail 2007, 9:136-143.
5. Maurer M.S. Heart failure with a normal ejection fraction (HFNEF): embracing complexity. J Card Fail 2009, 15:561-564.
6. Nishikawa N., Yamamoto K., Sakata Y., et al. Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation. Cardiovasc Res 2003, 57:766-774.
7. Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007, 87:1285-1342.
8. Yamazaki T., Lee J.D., Shimizu H., Uzui H., Ueda T. Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure. Eur J Heart Fail 2004, 6:41-45.
9. Barton P.J., Birks E.J., Felkin L.E., et al. Increased expression of extracellular matrix regulators TIMP1 and MMP1 in deteriorating heart failure. J Heart Lung Transplant 2003, 22:738-744.
10. Banfi C., Cavalca V., Veglia F., et al. Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure. Eur Heart J 2005, 26:481-488.
11. Frantz S., Stork S., Michels K., et al. Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: an independent predictor of mortality. Eur J Heart Fail 2008, 10:388-395.
12. Wilson E.M., Gunasinghe H.R., Coker M.L., et al. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail 2002, 8:390-398.
13. George J., Patal S., Wexler D., et al. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J 2005, 150:484-487.
14. Radauceanu A., Ducki C., Virion J.M., et al. Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure. J Card Fail 2008, 14:467-474.
15. Cicoira M., Rossi A., Bonapace S., et al. Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. J Card Fail 2004, 10:403-411.
16. Martos R., Baugh J., Ledwidge M., et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007, 115:888-895.
17. Westermann D., Lindner D., Kasner M., et al. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail 2011, 4:44-52.
18. Ahmed S.H., Clark L.L., Pennington W.R., et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006, 113:2089-2096.
19. Lang R.M., Bierig M., Devereux R.B., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18:1440-1463.
20. Nagueh S.F., Appleton C.P., Gillebert T.C., et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009, 10:165-193.
21. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
22. Barasch E., Gottdiener J.S., Aurigemma G., et al. Association between elevated fibrosis markers and heart failure in the elderly: the cardiovascular health study. Circ Heart Fail 2009, 2:303-310.
23. Martos R., Baugh J., Ledwidge M., et al. Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. Eur J Heart Fail 2009, 11:191-197.
24. Kitzman D.W., Little W.C., Brubaker P.H., et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002, 288:2144-2150.
25. Bursi F., Weston S.A., Redfield M.M., et al. Systolic and diastolic heart failure in the community. JAMA 2006, 296:2209-2216.
26. Lopez B., Gonzalez A., Querejeta R., Larman M., Diez J. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol 2006, 48:89-96.
27. Iwanaga Y., Nishi I., Furuichi S., et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol 2006, 47:742-748.
28. Maeder M.T., Mariani J.A., Kaye D.M. Hemodynamic determinants of myocardial B-type natriuretic peptide release: relative contributions of systolic and diastolic wall stress. Hypertension 2010, 56:682-689.
29. Costello-Boerrigter L.C., Boerrigter G., Redfield M.M., et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 2006, 47:345-353.
30. Dickstein K., Cohen-Solal A., Filippatos G., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008, 10:933-989.
31. Maisel A.S., McCord J., Nowak R.M., et al. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 2003, 41:2010-2017.
32. Yan A.T., Yan R.T., Spinale F.G., et al. Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure. Eur J Heart Fail 2008, 10:125-128.
33. Iraqi W., Rossignol P., Angioi M., et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 2009, 119:2471-2479.
34. Vorovich E.E., Chuai S., Li M., et al. Comparison of matrix metalloproteinase 9 and brain natriuretic peptide as clinical biomarkers in chronic heart failure. Am Heart J 2008, 155:992-997.
35. Maeda K., Tsutamoto T., Wada A., Hisanaga T., Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998, 135:825-832.
36. Yoshimura M., Yasue H., Okumura K., et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993, 87:464-469.
37. Chapman D., Weber K.T., Eghbali M. Regulation of fibrillar collagen types I and III and basement membrane type IV collagen gene expression in pressure overloaded rat myocardium. Circ Res 1990, 67:787-794.
38. Zile M.R., Desantis S.M., Baicu C.F., et al. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail 2011, 4:246-256.